--- title: "AC Immune (NASDAQ:ACIU) Stock Passes Above 50-Day Moving Average - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/296314317.md" description: "AC Immune (NASDAQ:ACIU) stock crossed above its 50-day moving average, trading at $2.57. Analysts maintain a consensus 'Hold' rating with an average price target of $7.50, though BTIG issued a 'Buy' rating with an $8.00 target. The company recently reported quarterly earnings of $0.03 per share, beating estimates, with revenue of $18.67 million. Institutional investors, including Goldman Sachs, have increased their stakes, holding over 51% of the shares." datetime: "2026-08-19T07:00:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296314317.md) - [en](https://longbridge.com/en/news/296314317.md) - [zh-HK](https://longbridge.com/zh-HK/news/296314317.md) generator: "portal-rs" --- # AC Immune (NASDAQ:ACIU) Stock Passes Above 50-Day Moving Average - Here's Why AC Immune (NASDAQ:ACIU - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.39 and traded as high as $2.59. AC Immune shares last traded at $2.57, with a volume of 90,179 shares changing hands. ## Analysts Set New Price Targets Several research analysts have commented on ACIU shares. HC Wainwright reaffirmed a "buy" rating on shares of AC Immune in a research note on Wednesday, July 1st. Weiss Ratings reissued a "sell (e+)" rating on shares of AC Immune in a research note on Wednesday, August 5th. Finally, BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of AC Immune in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, AC Immune has a consensus rating of "Hold" and an average target price of $7.50. **Read Our Latest Report on ACIU** ## AC Immune Stock Up 1.6% The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. The stock has a market cap of $261.55 million, a P/E ratio of -4.76 and a beta of 1.59. The company's 50 day moving average price is $2.39 and its two-hundred day moving average price is $2.71. AC Immune (NASDAQ:ACIU - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The business had revenue of $18.67 million during the quarter, compared to analysts' expectations of $9.59 million. As a group, research analysts expect that AC Immune will post -0.6 earnings per share for the current year. ## Institutional Trading of AC Immune A number of hedge funds have recently added to or reduced their stakes in ACIU. Goldman Sachs Group Inc. lifted its holdings in AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock worth $58,000 after buying an additional 5,920 shares during the period. EFG International AG purchased a new position in shares of AC Immune in the 4th quarter valued at $41,000. Private Advisor Group LLC purchased a new position in shares of AC Immune in the 3rd quarter valued at $48,000. Susquehanna International Group LLP bought a new position in shares of AC Immune in the 3rd quarter worth $63,000. Finally, Sei Investments Co. bought a new position in shares of AC Immune in the 2nd quarter worth $51,000. 51.36% of the stock is owned by hedge funds and other institutional investors. ## AC Immune Company Profile (Get Free Report) AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates. Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. ## Featured Articles - Five stocks we like better than AC Immune - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in AC Immune Right Now? Before you consider AC Immune, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list. While AC Immune currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ACIU.US](https://longbridge.com/en/quote/ACIU.US.md) - [GS-C.US](https://longbridge.com/en/quote/GS-C.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [GS-A.US](https://longbridge.com/en/quote/GS-A.US.md) - [GS-D.US](https://longbridge.com/en/quote/GS-D.US.md) - [SEIC.US](https://longbridge.com/en/quote/SEIC.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [WEN.US](https://longbridge.com/en/quote/WEN.US.md) - [HD.US](https://longbridge.com/en/quote/HD.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [Goldman Sachs trims Gerresheimer voting rights to 18.01% from 18.62%](https://longbridge.com/en/news/296493196.md) - [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md) - [Goldman Sachs voting rights in Hypoport slip to 4.95% from 5.09%](https://longbridge.com/en/news/296349944.md) - [Goldman Sachs lifts K+S voting rights to 12.18% from 7.24%](https://longbridge.com/en/news/296186403.md) - [Goldman Sachs lifts Aurubis voting rights to 12.37% from 11.79%](https://longbridge.com/en/news/296369399.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**